European urology oncology




One-year access to more than 500 world journals available in the system
    http://medilib.ir
  • Duration of Time : 365 Day
  • Price : 300$
  • Special Price : 100$
Order

Editorial Board

doi : 10.1016/S2588-9311(24)00197-4

Volume 7, Issue 5, October 2024, Pages i-ii

Buy The Package and View The Article Online



Surgery Remains an Integral Part of Multimodal Treatment for High-risk Prostate Cancer

doi : 10.1016/j.euo.2024.06.011

Buy The Package and View The Article Online


Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity

doi : 10.1016/j.euo.2024.06.001

Buy The Package and View The Article Online


Stratification of Patients with Renal Cell Carcinoma by the Abundance of Sarcomatoid Features Reveals Differences in Survival and the Underlying Pathobiology

doi : 10.1016/j.euo.2024.02.007

Buy The Package and View The Article Online


A Comprehensive National Survey of Prostate-specific Antigen Testing and Prostate Cancer Management in France: Uncovering Regional and Temporal Disparities

doi : 10.1016/j.euo.2024.02.008

Buy The Package and View The Article Online


Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Trial

doi : 10.1016/j.euo.2024.03.008

Buy The Package and View The Article Online


Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712

doi : 10.1016/j.euo.2024.03.015

Buy The Package and View The Article Online


How Can Participant Experience of Quality-of-Life Research Be Improved in Cancer Research: Views of the Patient and Public Involvement Representatives from the STAMPEDE2 Prostate Cancer Trial

doi : 10.1016/j.euo.2024.07.012

Buy The Package and View The Article Online


Risk of Fractures and Falls in Men with Advanced or Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy and Treated with Novel Androgen Receptor Signalling Inhibitors: A Systematic Review and Meta-analysis of Randomised Controlled Trials

doi : 10.1016/j.euo.2024.01.016

Buy The Package and View The Article Online


Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis

doi : 10.1016/j.euo.2024.03.014

Buy The Package and View The Article Online


Fluorine-18–labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL)

doi : 10.1016/j.euo.2024.01.002

Buy The Package and View The Article Online


External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial

doi : 10.1016/j.euo.2024.01.004

Buy The Package and View The Article Online


Propensity-matched Analysis of Open Versus Robotic Primary Retroperitoneal Lymph Node Dissection for Clinical Stage II Testicular Cancer

doi : 10.1016/j.euo.2024.01.006

Buy The Package and View The Article Online


Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial

doi : 10.1016/j.euo.2024.01.008

Buy The Package and View The Article Online


A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)

doi : 10.1016/j.euo.2024.01.009

Buy The Package and View The Article Online


Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy

doi : 10.1016/j.euo.2024.01.010

Buy The Package and View The Article Online


Association of Age with Non–muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?

doi : 10.1016/j.euo.2024.01.011

Buy The Package and View The Article Online


Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1)

doi : 10.1016/j.euo.2024.01.019

Buy The Package and View The Article Online


Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study

doi : 10.1016/j.euo.2024.02.005

Buy The Package and View The Article Online


Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

doi : 10.1016/j.euo.2024.03.001

Buy The Package and View The Article Online


Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy

doi : 10.1016/j.euo.2024.03.002

Buy The Package and View The Article Online


Performance of a Region of Interest–based Algorithm in Diagnosing International Society of Urological Pathology Grade Group ≥2 Prostate Cancer on the MRI-FIRST Database—CAD-FIRST Study

doi : 10.1016/j.euo.2024.03.003

Buy The Package and View The Article Online


Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study

doi : 10.1016/j.euo.2024.03.011

Buy The Package and View The Article Online


Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study

doi : 10.1016/j.euo.2024.03.013

Buy The Package and View The Article Online


Removing Barriers to the Use of Systemic Agents for Patients with von Hippel-Lindau Disease

doi : 10.1016/j.euo.2024.01.003

Buy The Package and View The Article Online


The Role of Cytomegalovirus in Prostate Cancer Incidence and Mortality

doi : 10.1016/j.euo.2024.02.004

Buy The Package and View The Article Online


A Case Series Study of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Early Evaluation of the Response to Systemic Therapy in Metastatic Renal Cancer

doi : 10.1016/j.euo.2024.02.006

Buy The Package and View The Article Online


Re: Michael S. Hofman, Louise Emmett, Shahneen Sandhu, et al. Overall Survival with [177Lu]Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-resistant Prostate Cancer (TheraP): Secondary Outcomes of a Randomised, Open-label, Phase 2 Trial. Lancet Oncol 2024;25:99–107

doi : 10.1016/j.euo.2024.02.001

Buy The Package and View The Article Online


Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti’s Letter to the Editor re: Piet Ost, Shankar Siva, Sugmund Brabrand, et al. PEACE V—Salvage Treatment of Oligorecurrent Nodal Prostate Cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007

doi : 10.1016/j.euo.2024.02.002

Buy The Package and View The Article Online


Re: Ost P, Siva S, Brabrand S, et al. PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007

doi : 10.1016/j.euo.2024.01.018

Buy The Package and View The Article Online


Reply to Marco Bandini, Andrea Salonia, and Francesco Montorsi’s Letter to the Editor re: Laura Elst, Manon T.A. Vreeburg, Hielke Martijn de Vries, et al. Corporal Skip Metastases in Penile Squamous Cell Carcinoma: An Unknown and Distinct Pattern of Spread with Poor Prognosis. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.005

doi : 10.1016/j.euo.2024.03.004

Buy The Package and View The Article Online


Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.11.008

doi : 10.1016/j.euo.2024.02.011

Buy The Package and View The Article Online


Do you want to add Medilib to your home screen?